Insulin Detemir
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
Insulin Detemir: From Diabetes Mellitus (Basal Insulin) to Type 1 Diabetes Mellitus
One-Sentence Summary
Insulin detemir (Levemir) is a long-acting basal insulin analogue used to manage diabetes mellitus. The TxGNN model predicts it is effective for Type 1 Diabetes Mellitus, supported by 50 registered clinical trials and 19 publications. This is largely an on-label use rather than true repurposing, so the high score mainly confirms a known drug-disease link.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Diabetes mellitus, basal insulin therapy (no indication text is recorded in the SAHPRA entry supplied) |
| Predicted New Indication | Type 1 diabetes mellitus |
| TxGNN Prediction Score | 99.77% |
| Evidence Level | L1 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 1 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Insulin detemir is a soluble, long-acting human insulin analogue with a 14-carbon fatty acid attached. The fatty acid lets it bind reversibly to albumin. This slows absorption after injection and gives a prolonged, more predictable glucose-lowering effect of up to 24 hours, with less variability than NPH insulin. It acts on the insulin receptor to replace the insulin that is missing in type 1 diabetes.
Type 1 diabetes is defined by loss of endogenous insulin, so basal insulin replacement is the core treatment. The published reviews describe detemir as a basal insulin option for both type 1 and type 2 diabetes. The TxGNN score therefore reflects an established drug-disease relationship, not a new mechanism.
The other nine predictions (ranks 2–10) have no trials or literature and are all L5 (model prediction only). Most look like graph-neighbourhood noise or comorbidity links, such as autoimmune oophoritis and stiff person syndrome, which overlap with T1DM autoimmunity. The localized lipodystrophy entries likely reflect a known injection-site adverse effect of insulin, not a treatment opportunity. Pancreatic agenesis is biologically plausible, since insulin is standard supportive care for the resulting diabetes, but no evidence was supplied. None of these should be read as new indications.
Clinical Trial Evidence
Ten of the 50 registered trials are shown, chosen for relevance, size and African participation.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01486940 | Phase 3 | Completed | 598 | Detemir + aspart vs NPH + human soluble insulin in T1DM on a basal-bolus regimen; glycaemic control comparison |
| NCT03220425 | Phase 3 | Completed | 752 | Six-month efficacy and safety of detemir (2400 nmol/mL formulation) vs NPH in T1DM |
| NCT00447382 | Phase 3 | Completed | 330 | 12-month double-blind safety comparison of two detemir manufacturing processes in T1DM; sites included South Africa |
| NCT00095082 | Phase 3 | Completed | 447 | Detemir vs glargine (both with aspart) in T1DM; tests whether detemir is at least as effective |
| NCT00474045 | Phase 3 | Completed | 470 | Detemir vs NPH (with aspart) in pregnant women with T1DM; sites included Africa |
| NCT01513473 | Phase 3 | Completed | 350 | Insulin degludec vs detemir in children and adolescents with T1DM (BEGIN Young 1); sites included Africa |
| NCT00738153 | N/A (observational) | Completed | 798 | Efficacy and serious adverse drug reactions of Levemir in routine care in Africa; mixed type 1 and 2 population |
| NCT01461616 | Phase 3 | Completed | 19 | Triple crossover of NPH, detemir and glargine on IGFBP-1 and IGF-I in T1DM |
| NCT00595374 | Phase 3 | Completed | 114 | Detemir + aspart vs NPH + aspart on blood glucose control in adults with T1DM |
| NCT00487240 | Phase 3 | Completed | 387 | Insulin lispro protamine vs detemir as basal insulin in T1DM |
No SANCTR or PACTR identifiers were included in the data supplied.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36623517 | 2023 | RCT | Lancet Diabetes Endocrinol | EXPECT: open-label, non-inferiority trial of degludec vs detemir (both with aspart) in pregnant women with T1DM |
| 36763996 | 2022 | Meta-analysis | Clin Ther | Efficacy and tolerability of degludec vs glargine and detemir in T1D and T2D |
| 29477399 | 2018 | Network meta-analysis | Value Health | Relative efficacy and safety of basal insulin regimens in adults with T1DM |
| 21878861 | 2011 | Meta-analysis | Pol Arch Med Wewn | Detemir vs NPH insulin in T1DM; the benefit of detemir has not been confirmed by all investigators |
| 23110609 | 2012 | Review | Drugs | Detemir as basal insulin in T1DM and T2DM; less within-patient variability than NPH in glucose-clamp studies |
| 15516157 | 2004 | Review | Drugs | Albumin binding gives a prolonged, consistent effect of up to 24 hours; more predictable than NPH |
| 20539842 | 2010 | Review | Vasc Health Risk Manag | Basal analogue with lower hypoglycaemia rates; no significant HbA1c difference vs comparators |
| 17326333 | 2006 | Review | Vasc Health Risk Manag | Less variable pharmacokinetics than NPH or ultralente; may reduce hypoglycaemia, especially nocturnal |
| 37290466 | 2023 | Review | Lancet Diabetes Endocrinol | Update on T1DM in pregnancy: glycaemic targets, pharmacological treatment and technology |
| 18454569 | 2008 | Review | Paediatr Drugs | Insulin analogues, including detemir, in children and adolescents with T1DM |
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. 38/21.1/0084 | Levemir prefilled cartridge 3ml | Injection | Not stated in the record supplied |
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Several completed Phase 3 trials (n = 330–752) directly compare detemir in type 1 diabetes, and systematic reviews and meta-analyses support the same use. This is basal insulin replacement for a labelled use, so it is not true repurposing. The other nine predictions have no evidence and should stay on Hold or be treated as research questions.
To proceed, the following is needed:
- Confirm the approved indication for registration 38/21.1/0084 against the SAHPRA record and Professional Information. The indication text is blank in the data supplied.
- Retrieve the PI warnings and contraindications, which are needed for safety screening.
- Monitor hypoglycaemia and body weight, and individualise dosing.
- Watch for injection-site lipodystrophy, a recognised insulin effect that may explain the lipodystrophy predictions.
- Confirm the truncated trial records (for example NCT01513473, NCT03220425 and NCT00447382) before citing them as detemir efficacy evidence.
This report is for research reference only and is not medical advice. Predictions require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.